Nu Skin Enterprises, Inc. (NUS) Analysts See $0.67 EPS

April 19, 2018 - By Adrian Erickson

Nu Skin Enterprises, Inc. (NYSE:NUS) LogoInvestors sentiment increased to 1.16 in Q4 2017. Its up 0.09, from 1.07 in 2017Q3. It is positive, as 19 investors sold Nu Skin Enterprises, Inc. shares while 75 reduced holdings. 42 funds opened positions while 67 raised stakes. 37.52 million shares or 2.40% less from 38.44 million shares in 2017Q3 were reported.
Balasa Dinverno And Foltz Limited holds 0.03% or 3,383 shares in its portfolio. Us Bancshares De accumulated 2,230 shares. Moreover, Eagle Boston Invest Mgmt Inc has 0.81% invested in Nu Skin Enterprises, Inc. (NYSE:NUS) for 118,164 shares. Louisiana State Employees Retirement owns 0.04% invested in Nu Skin Enterprises, Inc. (NYSE:NUS) for 12,500 shares. Ameriprise Fincl owns 170,461 shares for 0.01% of their portfolio. Suntrust Banks Inc reported 4,209 shares. Aperio Grp Inc Ltd Com has invested 0.02% of its portfolio in Nu Skin Enterprises, Inc. (NYSE:NUS). Utah Retirement holds 9,600 shares. Jennison Associate Ltd Liability holds 0% in Nu Skin Enterprises, Inc. (NYSE:NUS) or 25,571 shares. Oregon Public Employees Retirement Fund has 18,311 shares for 0.02% of their portfolio. Raymond James Associate has invested 0% in Nu Skin Enterprises, Inc. (NYSE:NUS). Robeco Institutional Asset Management Bv accumulated 59,388 shares. The Connecticut-based Aqr Mngmt Ltd Liability Co has invested 0.12% in Nu Skin Enterprises, Inc. (NYSE:NUS). Washington Trust Comml Bank, Washington-based fund reported 1,514 shares. Vident Advisory Lc stated it has 0.13% of its portfolio in Nu Skin Enterprises, Inc. (NYSE:NUS).

Since January 19, 2018, it had 0 buys, and 8 insider sales for $116.91 million activity. Another trade for 3,250 shares valued at $234,716 was made by DORNY D MATTHEW on Monday, April 2. Lawrence Mark H also sold $52,751 worth of Nu Skin Enterprises, Inc. (NYSE:NUS) on Thursday, March 8. On Friday, January 19 the insider LUND STEVEN sold $1.60M. Thomas Pisano R. also sold $1.08 million worth of Nu Skin Enterprises, Inc. (NYSE:NUS) on Wednesday, March 7.

Analysts expect Nu Skin Enterprises, Inc. (NYSE:NUS) to report $0.67 EPS on April, 26 after the close.They anticipate $0.16 EPS change or 31.37 % from last quarter’s $0.51 EPS. NUS’s profit would be $36.37M giving it 26.50 P/E if the $0.67 EPS is correct. After having $1.20 EPS previously, Nu Skin Enterprises, Inc.’s analysts see -44.17 % EPS growth. The stock decreased 0.95% or $0.68 during the last trading session, reaching $71.01. About 223,019 shares traded. Nu Skin Enterprises, Inc. (NYSE:NUS) has risen 33.34% since April 19, 2017 and is uptrending. It has outperformed by 21.79% the S&P500.

Nu Skin Enterprises, Inc. (NYSE:NUS) Ratings Coverage

Among 3 analysts covering Nu Skin (NYSE:NUS), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Nu Skin had 4 analyst reports since January 23, 2018 according to SRatingsIntel. The rating was downgraded by Deutsche Bank to “Hold” on Friday, April 13. The rating was maintained by Stifel Nicolaus on Thursday, February 15 with “Sell”. The company was maintained on Friday, February 16 by Deutsche Bank.

Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. The company has market cap of $3.86 billion. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC Transformation anti-aging skin care systems; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products. It has a 30.09 P/E ratio. The firm also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, and LifePak nutritional supplements, as well as other anti-aging nutritional solutions and weight management products.

Nu Skin Enterprises, Inc. (NYSE:NUS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: